Biogen says it received a subpoena from the feds in December relating to rebate payments and Biogen's co-pay assistance programs for Tecfidera and other…

After a string of setbacks, Bristol-Myers Squibb was badly in need of some good news on the immuno-oncology front, and Thursday, that’s what it got.

The EpiPen saga isn’t over. The FTC is investigating Mylan's efforts to stave off generic versions of its blockbuster device.

Pharma CEOs got marching orders from President Trump on Tuesday morning: Lower "astronomical" prices, give us "better innovation" and make…

Johnson & Johnson CEO Alex Gorsky said there are aspects of the ACA that can help patients and lower costs for the country and should be maintained.

​​​​​​​AstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA, putting it in line for hundreds of millions in…

A top U.S. health official says there’s no settlement with Mylan, adding yet another twist to the company’s prolonged EpiPen episode.

​​​​​​​Patients in the U.K. face yet another barrier to access with reports the country is considering drug rationing.

Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients…

Regulatory